Nextage Therapeutics Ltd. (TASE:NXTG) (“Nextage” or the “Company”), an Israeli drug development company and its psychedelic pharmaceutical development dedicated subsidiary IMIO Life Ltd, ( “IMIO” jointly to be referred to as “The Group”) are pleased to announce positive pre- clinical acute toxicity results for the proprietary BTLS delivery technology.
The group believes that these initial results are a significant milestone in the clinical development of its pipeline of proprietary novel therapies based on the BTLS technology. These results add substantial value to the group’s ability to commercialize and partner with other pharmaceutical companies looking to develop brain and CNS targeted therapeutics.
During the pre-clinical study of acute toxicity of both the BTLS delivery by itself (not loaded with any API) as well as a CBD loaded delivery system were examined. A 14 day observation as well as a detailed pathological examination have showed no indication of toxicity.
The completion of this milestone has contributed to the advancement of the groups’ BTLS platform allowing it to advance its clinical programs aiming at reducing the systemic effect and reducing needed concentrations of several API’s including Ibogaine and Noribogaine as well as cannabinoids.
The BTLS nano technology is an innovative drug delivery system designed to allow the targeted delivery of active pharmaceutical ingredients (APIs) through the Blood Brain Barrier. BTLS is designed to reduce exposure to the active material outside of the brain, reducing potential risks, intended to substantially lower API concentrations and increasing efficacy.
In May 2021 IMIO announced the launch of an exclusive collaborative development program with MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ) to optimize the delivery of Noribogaine and other Ibogaine derivatives, leveraging Nextage’s proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on Noribogaine and other Ibogaine derivatives. Utilizing Nextage’s proprietary brain-targeted liposome system, the collaboration will seek to develop a proprietary formulation aimed at minimizing the systemic exposure of Ibogaine derivatives while maintaining effective concentrations in the brain, with the objective of significantly improving the risk-benefit profile of their delivery.
Nextage CEO, Mr. Abraham Dreazen, said: “These positive indications provide a much necessary data required bringing our proprietary BTLS delivery system one step closer to clinical evaluation. Our innovative delivery technology has the potential to open the door to a new world of brain and CNS treatment and this is a substantial step towards advancing our pipeline projects and some new and exciting collaborations”
About Nextage Therapeutics ltd.
Nextage Therapeutics is a pharmaceutical development company specializing in the development of innovative cannabis and psychedelic based therapies. Nextage is led by CEO Mr. Abraham Dreazen and Chairman Mr. Israel Makov, the former CEO of Teva Pharmaceuticals. In the psychedelic field Nextage operates via its dedicated subsidiary IMIO Life. Nextage is a subsidiary of Nextar Chempharma Solutions, Israel’s leading full service contract development and manufacturing company for pharmaceuticals and chemical medical devices.
About IMIO Life ltd.
IMIO Life is a pharmaceutical company dedicated to developing novel solutions targeting high impact chronic pain. IMIO’s proprietary BTLS technology is a groundbreaking drug delivery system that allows the targeted delivery of API’s through the blood-brain-barrier minimizing systemic exposure and side effects and increasing brain availability.
IMIO focuses on developing with psychoactive compounds to develop new solutions for debilitating unmet needs. IMIO is a subsidiary of Nextage Therapeutics LTd. a public company on the Tel Aviv stock exchange (NXTG:TASE) and part of the Nextar group, giving it access to fully vertical pharmaceutical development and manufacturing experience and infrastructure.
Forward Looking Statements
This press release contains express or implied forward-looking statements within the Israeli Securities Law 5728-1968. These forward-looking statements and their implications are based on the current expectations of the management of Nextage only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, Nextage undertakes no obligation to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
